BBVA USA’s Haemonetics HAE Stock Holding History

BBVA USA’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$81K	Buy	1,154 +713	+162%	+$45K	﹤0.01%	575
2021 Q2	$29K	Buy	+441	New	+$31.2K	﹤0.01%	754

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBVA USA's HAE Position: Q3 2021 in Review

BBVA USA increased its Haemonetics (HAE) stake by 162% in Q3 2021, buying an estimated $45K and bringing the position to 1,154 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #575.

BBVA USA first reported a position in HAE in Q2 2021 and has held it in 2 quarters since. 245 funds tracked by Wall St. Rank hold HAE as of Q3 2021.

BBVA USA held 1,154 shares of Haemonetics worth $81K as of Q3 2021.
BBVA USA bought 713 Haemonetics shares in Q3 2021, an estimated $45K.
Haemonetics made up ﹤0.01% of BBVA USA's portfolio in Q3 2021, its #575 holding.
BBVA USA first reported a position in Haemonetics in Q2 2021 and has held it in 2 quarters since.
245 funds tracked by Wall St. Rank held Haemonetics as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.